The present study describes the effects of losartan and the angiotensin-converting enzyme inhibitor enalapril on blood pressure, echocardiographically calculated left ventricular mass, renal function evaluated by glomerular filtration rate and quality of life. The renin-angiotensin-aldosterone system is of importance for cardiovascular growth. There is substantial experimental documentation in animals that the angiotensin II antagonist, losartan, decreases the cardiac hypertrophy response caused by elevated arterial pressure as well as intravascular volume overload. However, data in humans is scarce. This is a 3-year, randomised, doubleblind study with parallel group design in 50 patients with essential hypertension. The results show that both drugs reduced blood pressure equally effectively, and also left ventricular mass (P Ͻ 0.001). After 3 years of treatment glomerular filtration rate significantly increased with losartan (P Ͻ 0.005). Serum uric acid fell modestly although significantly, dose-dependent in los-
Introduction
After more than 10 years of continuously increasing clinical use of angiotensin-converting enzyme (ACE) inhibitors, blockade of the renin-angiotensin system has become a well accepted treatment for hypertension and congestive heart failure. The renin-angiotensin cascade starts with the cleavage of angiotensinogen by renin to form angiotensin I and culminates in conversion of the inactive decapeptide angiotensin II. At present this system can be blocked at two other sites besides that of ACE inhibition. One approach is to inhibit renin. This is a more specific enzyme than ACE and therefore represents an inter-artan patients compared with an increase in enalapril patients. A fall in serum potassium from the pre-study period was observed in all patients. There was no difference between treatments in terms of patient satisfaction on quality of life. Both drugs have relatively similar hormonal and haemodynamic effect, with an excellent tolerability profile; they appear to induce comparable blood pressure falls in hypertensive patients in particular, therapy based on specific Ang II blockade may offer advantages in high risk hypertensives if left ventricular hypertrophy is present. Both enalapril and losartan, in improving the renal function attenuating the intrarenal effects of angiotensin II, might be able to reverse the pathophysiology of essential hypertensive kidney disease, and should be first-choice drugs in the treatment of essential hypertension. esting therapeutic target, at least theoretically. So far, however, it has been difficult to develop good candidate molecules for clinical use. The angiotensin II receptor is another site where the renin-angiotensin system can be blocked. Recently, several angiotensin II antagonists have been developed, and over the last few years experimental and clinical experience with these compounds has grown rapidly. 1 Although both ACE inhibitors and angiotensin II antagonists aim at suppressing the activity of the renin-angiotensin system, there are interesting differences between the two therapeutic approaches. Angiotensin II antagonists are certainly more specific, but as a higher specificity is expected to reduce the incidence of side effects, these antagonists may conceivably have less therapeutic efficacy than ACE inhibitors. On the basis of the experience that has now been accumulated with the use of angiotensin II antagonists, this paper reviews the potential advantages and disadvantages of these agents, comparing their effects, efficacy, and side effects with those of ACE-inhibitors.
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Losartan potassium (losartan DuP753) is an orally active and highly selective antagonist of angiotensin II (Ang II) at the type 1 (AT1) receptor. 2 Clinical pharmacology studies have confirmed that losartan blocks the Ang II receptor. 3 Clinical trials have demonstrated that losartan potassium given alone lowers blood pressure (BP) and is well tolerated in longterm trials in patients with essential hypertension. 4 Despite the efficacy of losartan potassium or other monotherapy agents such as hydrochlorothiazide (HCTZ), some patients with more resistant forms of hypertension may require concomitant antihypertensive therapy to control their BP. 5 The purpose of this 3-year trial was to assess the long-term effects of ACE inhibitors (enalapril) vs selective AT1 receptor blockade (losartan) on reactive cardiac hypertrophy and on renal function in patients with mild to moderate essential hypertension.
Subjects and methods

Subjects
Fifty patients, 25 female and 25 male, with essential hypertension, mean age 52 ± 77 years, classified as WHO stage II (average supine diastolic BP (DBP) Ͼ90 mm Hg and/or systolic BP (SBP) Ͼ140 mm Hg), measured according to the recommendations of the American Heart Association, were recruited from our out-patient clinic and included in a trial comparing the efficacy of losartan and enalapril in treating essential hypertension. Patient eligibility was established by a complete medical history, physical examination, and laboratory screening including a complete blood count with measurements of serum electrolytes, blood urea nitrogen, creatinine, transaminases, alkaline phosphates, urinolysis and electrocardiogram. Their baseline characteristics are given in Table 1 . All patients were previously treated with antihypertensive drugs. However, there were no differences with regard to the previously used classes of drugs between the groups. All antihypertensive treatment was withdrawn at least 7 full days before the start of the placebo period (the most commonly used antihypertensive drugs overall were lisinopril, HCTZ, diltiazem and nifedipine). Exclusion criteria also included significant cardiovascular, cerebrovascular, renal or hepatic disease, recent myocardial infarction and secondary hypertension. Patients with clinically significant laboratory abnormalities were also excluded. They were not on a sodium-restricted or other special diet.
Study protocol
After a 2-week placebo run-in, patients were randomised to 3 years of active therapy of double-blind treatment, either to enalapril 5 mg titrated to 10 and then 20 mg once daily (+ placebo for losartan) or to losartan 12.5 mg, titrated to 25 and then 50 mg once daily (+ placebo for enalapril) in a parallel group design ( Figure 1 ). Titration generally occurred at 7-day intervals as tolerated if DBP was у90 mm Hg. Patients were seen in the ambulatory unit of our clinic by one of the authors after 1, 2, 3 and 4 weeks and every 12 weeks of the 3-year double-blind therapy. During the placebo baseline period, all participants received two tablets daily, one placebo tablet matching losartan, one placebo tablet matching enalapril. The patients were monitored every 2 weeks for vital signs and adverse experiences. Laboratory assessment was obtained after the 2-week placebo period. No antihypertensive drugs other than the study drugs were allowed during the study. The study was approved by an institutional review committee; all participants were required to provide written informed consent and the procedures followed were in accordance with institutional guidelines; quality of life questionnaires were also completed by all participants.
Blood pressure measurements
The BP measurement used for assessment of efficacy in this study was a trough sitting DBP (SiDBP) and SBP (SiSBP) measurement in the right arm after 5 min of rest taken 22 to 26 hours after ingestion of the last dose of the study medication. Blood pressure was measured with a standard mercury sphygmomanometer by clinic personnel who were certified through a standardised training programme according to the American Heart Association guidelines for the measurement of BP and the disappearance of Korotkoff pulse sound. Heart rates were measured for 30 s with patients in the sitting and standing position before the receptive BP measurement at each visit. Patients with two mean trough SiDBP measurements between 95 and 114 mm Hg inclusive, that did not differ by more than 7 mm Hg, inclusive, at week 2 of the placebo baseline period and with no exclusion criteria were considered eligible for entry into the active treatment period. BP was measured at 1-min intervals, at least three times, until stability was obtained, ie, none of the three consecutive sitting DBP measurements was 25 mm Hg from the calculated average of the readings. The average of these reading was used in the statistical analysis. Mean arterial pressure (MAP) was calculated as:
Echocardiography
M-B mode echocardiograms were obtained from all patients at our centre using standard equipment and a validated procedure at baseline and after 1, 2 and 3 years of active treatment. 6 An Acuson 128 Cardiovascular System with a 2.25 Mhz phased array sector scanned was used. The M-B mode echocardiographic recordings were guided by two-dimensional routine views. The echocardiograms were performed after at least a 5-min rest, with the subject in the left lateral position, with the head of the bed slightly elevated. The transducer was placed in third or fourth left intercostal space parasternally, and the ultrasound beam directed to produce a simultaneous recording of the endothelial surfaces of the interventricular septum and the left posterior wall immediately below the plane of the tree edges of the mitral valve. Left ventricular structures were determined from M-B mode echocardiogram, using the heading edge to heading edge technique, as recommended by the American Society of Echocardiography. 7 Left ventricular mass (LVM) was calculated according to anatomically validated formula:
where LVID is the left ventricular internal diameter in diastole, IVST the ventricular septal thickness, and
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PWT the posterior wall thickness. 8 LVM index (LVMI) was defined as the LVM divided by the body surface area. Left ventricular hypertrophy was defined as LVMI Ͼ131 g/m 2 in men and Ͼ100 gr/m 2 in women. 6 All echocardiografic examinations and interpretations were made by the same examiner, not aware of the subject's BP, group affiliation or the results of the previous recording. All images were recorded so that a second blinded observer could validate them (agreement between the two observers and reproducibility of recordings by the same observer were within 1 mm). The variation coefficients for the determination of IVST, PWT and LVID at our echocardiographic laboratory are 6.6%, 5.2% and 2.8%, respectively. 
Renal scintigraphy
The computed radionuclide glomerular filtration rate (GFR) of the kidneys were assessed 2-3 min after a single IV injection of 3 mCi (111 MBq) of technetium-99 m diethylene-triaminepentaacetic acid (Tc 99 m-DTPA) using the method described by Gates.
10,11 The injected dose was measured by counting the syringe with a gamma camera (GE, Starport) using standardised geometry (at 30 cm). Renal scintigraphy was performed with the patient positioned upright using the same gamma camera equipped with a low-energy, parallel-hole collimator. Data acquisition was initiated at the moment of injection and recorded in computer memory every 15 s for 6 min. At the end of the study, each kidney was outlined by a region of interest.
Evaluation of patients
Clinical assessments with a following clinical examination were weekly during titration, and 1, 2 and 3 yearly thereafter. Before the study, at the end of titration phase and at the end the active treatment electrocardiogram, renal scintigraphy, quality of life measures and laboratory safety assessment profile were obtained.
Statistical methods
Baseline comparability of the treatment groups with respect to demographic and clinical characteristics was assessed using Student's t-test and Fisher's exact test. Changes in BP and pulse were analysed using the paired t-test for within-group differences and analysis of variance (ANOVA) for betweengroup differences. The ANOVA model included terms for overall mean, treatments, and level of pretreatment BP. The primary end-point of the study was the change in mean trough sitting BP from baseline to the end of study. Ninety-five percent confidence intervals (CI) for within-group changes from baseline as well as for between-group differences in change from baseline was calculated. Results were considered significant if P Ͻ 0.05.
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The incidence of adverse experience, abnormal laboratory findings, and clinically significant changes in physical examination and electrocardiogram were all considered in the evaluation of the study and tolerability of the two regimens. Differences in the overall incidence of adverse events were compared using Fisher's exact test.
A battery-of-scales questionnaire, composed of questions from previously validated questionnaires, was used to evaluate differences in quality of life. 12 Seven domains of health-related quality of life were included: symptom bother, overall health perceptions, psychologic well being, social functioning, sleep disturbance, cognitive functioning and sexual functioning. The symptom bother inventory, containing responses of 'not at all', 'little', 'moderately', 'quite a bit', or 'extremely', was used to assess changes in disease-and treatment-related complaints between baseline and year 3. Items from the symptom inventory were analysed individually. The percentage of patients who responded 'not at all' or 'little' to the first 31 items and 'no' to the final item as opposed to the percentage of those who responded 'moderately', 'quite a bit', or 'extremely' to the first 31 items and 'yes' to the final item was determined in each time period.
Differences between treatment groups were compared using chi-square test, and within-group changes were analysed via Mc Nemar's test. The symptoms included dry mouth, headaches, weakness in limbs, blurred vision, shortness of breath, swollen ankles, constipation, bad taste in mouth, feeling of burnt mouth, blocked or runny nose, nausea, rush on body, itching, cramps in legs, pain in joints and hands, shaky hands, racing heart, heart burn, sore throat, dry cough, sweating, wheezing, dry eyes, mouth ulcers, light sensitivity, cold hands or feet, nicturia, diarrhoea, flushing of face, heart pounding and faintness. The symptoms of swollen ankles, headache and flushing were emphasised. A Bonferroni correction for multiplicity was employed (alpha р0.017 for significance). For all other symptoms, treatment differences were considered significant at alpha р0.01. In addition, the domains of general health and sexual function were emphasised. A Bonferroni correction for multiplicity was used alpha р0.025 for comparing treatments with regard to these two domains. For four of the other six quality-of-life scales, differences between treatment groups were considered significant at an alpha level of 0.05. Quality-of-life indices, including treatment, studies, and their interaction were compared between treatment groups using an ANOVA model that included treatment, studies, and their interaction. Likewise, within-group changes were analysed using a paired t-test.
Echocardiographic data were analysed using Wilcoxon's sign ranking test. 
Results
Of the 50 patients who entered the active treatment phase, 42 completed all 3 years of therapy. The most common reason overall for withdrawal was adverse clinical experience ( Table 2 ). The most common experience reported during the placebo period was headache. Only patients treated with enalapril reported that it was considered drug related, rather than those patients treated with losartan.
In Table 3 SBP, DBP and MAP at baseline and after 3 years of active treatment are given. Both drugs reduced SBP, DBP and MAP equally effective (Figure 2 ). To adequately control BP, 13 patients on losartan (60%) and 15 patients on enalapril (78%) were given the higher dose after 4 weeks. Heart rate was not affected by either drug. The results of the ecocardiographic examinations are given in Table 4 .
Left ventricular diastolic dimension and septal and posterior wall thickness decreased significantly (P Ͻ 0.001), left ventricular mass index also decreased with both drugs. Figure 3 shows the effects of losartan or enalapril administration on GFR in all patients. Since 41% of all patients had basal values lower than normal, GFR increased significantly after 3 years of treatment with losartan (from 96.5 ± 32.3 to 108.6 ± 31.12 ml/min; P Ͻ 0.005) while with enalapril (from 94.8 ± 31.1 to 99.8 ± 19.6; P = 0.085), only in one losartan patient did GFR decrease.
Metabolic effects
During the placebo run-in period serum uric acid concentrations ranged from 378 to 395 mol/l in all
Journal of Human Hypertension patients. After 3 years of double-blind therapy, serum uric acid fell modestly although significantly in a dose-dependent fashion in patients that received losartan plus placebo compared with the increase in enalapril + placebo patients. A fall in serum potassium from the pre-study period was observed in all patients. During the 3 years of double-blind treatment, serum potassium remained essentially unchanged in losartan + placebo patients; in contrast a modest but not statistically significant reversal of the losartan-induced fall in serum potassium in enalapril + placebo patients.
Quality of life
The battery-of-scales quality of life instrument was administered at baseline and after 12 weeks of therapy. An important objective of this study was to compare the effect of losartan and enalapril regimens on the patient's quality of life with respect to: (a) general health, (b) sexual functioning, and (c) symptom bother due to headache, flushing, cough, hypotension, and oedema. There were no statistical differences between the two therapies in the domains of general health, sexual functioning, or for the other scales of quality of life.
In terms of patient-perceived symptom bother, there was no statistical difference between the losartan and the enalapril regimen in the domain of symptom bother due to headache and flushing; however, there was a significantly higher incidence of bother due to cough in the enalapril patients than
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In general, there were no treatment-related increases in the percentage of patients with orthostatic hypotension with losartan.
The lack of statistical differences between treatments for the remaining domains of the quality of life may be the result of inadequate sensitivity of the instrument to detect change or the lack of a true difference between these domains of the quality of life.
At the end of the 3-year active therapy period, patients answered a self-administered questionnaire regarding their satisfaction with the treatment they received during the study. There was no difference between treatments in terms of patient satisfaction. Approximately 60% of patients in each group were satisfied with their study therapy, and approximately 70% indicated that they would be willing to remain on that therapy.
Discussion
The present study describes the effects of the ACE inhibitor enalapril and the angiotensin II antagonist losartan on BP, LVM and renal function.
Effects on blood pressure and on left ventricula mass
In the present study enalapril and losartan lowered BP equally effective. The BP-reducing effect of losartan has previously been well established in animal models with spontaneous hypertension 14 as well as in patients with essential hypertension. 15 Based on the findings in a meta-analysis of 109 treatment trials it has been suggested that ACE inhibitors, as compared with other first-line antihypertensive drugs, may be superior in inducing regression of left ventricular hypertrophy. 16 In fact, the changes in the renin-angiotensin-aldosterone system (RAAS) explained approximately 50% of the change in cardiac structure and the superiority of the ACE-inhibitor was mainly explained by the blockade of the RAAS rather than the BP reduction per se.
Treatment with an ACE inhibitor is associated with a reduction in the plasma levels of Ang II, while specific blockade at the receptor level with losartan causes a rise in the plasma levels of Ang II. In this context it is important to recognise that the active peptide product, Ang II, has been shown to be a potent growth factor resulting in both vascular and cardiac hypertrophy. 17 However, it appears that not only the vasoconstrictor effect of Ang II, but almost all the known cardiovascular effects of Ang II, including the growth promoting effects, is mediated by the Ang II subtype 1 receptor (AT1), which is blocked by losartan. 18 In cardiac tissue ACE-inhibitor only inhibits a fraction of Ang II formed from Ang I, which suggests that other enzymes are involved. In this respect the recently described cardiac chymase system may be of interest. 19 Thus, blocking Ang II at its specific receptor sites with losartan would, at least in theory, result in a more complete inhibition of the effects of Ang II produced locally in the heart. Both enalapril and losartan significantly tended to reduce LVM; it should be kept in mind that the present study had not been designed to have enough power to adequately evaluate the efficacy of losartan compared with enalapril in reducing LVM. Obviously, the number of patients included in the present study was too small, thus making the results regarding LVM only indicative. Furthermore, the identification of alternative pathways of Ang II production, 19 as well as the recently observed association of DD ACE polymorphism with left ventricular hypertrophy recognised by ECG criteria, 20 suggest that specific Ang II blockade may even be superior to ACE inhibitors in reducing LVM.
Effects on glomerular filtration rate
The haemodynamic renal response to inhibition of the conversion of angiotensin I to angiotensin II is characterised by an increase in renal blood flow without any change in GFR; in consequence, the filtration fraction decreases. 21 In the regulation of renal haemodynamics, angiotensin II acts on both the afferent and the efferent arterioles. 22 The fact that the filtration fraction is reduced by ACE inhibitors suggest that angiotensin II acts predominantly on the efferent arterioles. Our data demonstrate that both enalapril and losartan significantly improves GFR after therapy, especially in those patients with a low basal GFR value. Thus, ACE inhibitors and angiotensin II antagonist appear to have relatively similar renal haemodynamic effects. It has been postulated that the renal haemodynamic changes induced by ACE inhibitors are not the result of a fall in plasma angiotensin II but rather of an increase in bradykinin, in prostaglandin or in some other factor. The results obtained so far with angiotensin II antagonists tend to suggest that angiotensin II is the predominant mediator of the ACE inhibitor effects on renal haemodynamics.
Metabolic effects
In some studies, the natriuresis induced by ACE inhibition was associated with a slight increase in urinary uric acid. In a pilot study, Nakashima et al 23 have shown that losartan significantly increases uric acid excretion. The uricosuric effect of losartan appears to be independent of the degree of activity of the RAAS as it was comparable with both types of sodium diet. In parallel to these changes in urinary uric acid elimination, plasma uric acid has been shown to decrease significantly after an acute or repeated administration of losartan. 24 Indeed, in salt-loaded volunteers, losartan has been shown to induce an increase in urinary potassium excretion instead of an expected decrease, due to inhibition of aldosterone secretion. 24 
Effects on quality of life
A dry, unproductive cough has been recognised as the most important class effect of ACE inhibitors and appears to be related mainly to ACE inhibition itself. 25 Because angiotensin II antagonists have no effect on ACE, a cough is very unlikely to develop during specific angiotensin II blockade. A larger study on the occurrence of coughing during losartan therapy is being conducted at present. The data results suggest that compared to lisinopril and a diuretic, losartan does not cause a cough. 26 As expected, dehydration or salt depletion favour the development of hypotension in patients treated with an ACE inhibitor. The risk may also occur if there are widespread vascular lesions within the kidney. 21 Clinical experience with angiotensin II antagonists is still too small to estimate the incidence of these side effects. However, there is no theoretical reason why these problems should not be observed during angiotensin II blockade unless the hypothesis concerning the mechanism of these unwanted effects is wrong.
